drugset / Trial / NCT07660341
SAD Study of CGB3002 in Healthy Participants
Phase 1
Recruiting
46 enrolled
ChainGen Biopharma Ltd
ChainGen Biopharma (Australia) Pty Ltd · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single ascending IV doses of CGB3002 in healthy participants. CGB3002 is being developed to treat Alzheimer's Disease.
Timeline
- Start
- 2026-06-30
- Primary completion
- 2027-04-30
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CGB3002 | Unknown | 0.08 mg/kg | Intravenous |
| Subject | CGB3002 | Unknown | 0.4 mg/kg | Intravenous |
| Subject | CGB3002 | Unknown | 1.2 mg/kg | Intravenous |
| Subject | CGB3002 | Unknown | 3.6 mg/kg | Intravenous |
| Subject | CGB3002 | Unknown | 7.2 mg/kg | Intravenous |